EVALUATION OF MINIMAL RESIDUAL DISEASE IN HIGH-RISK CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA USING AN IMMUNOLOGICAL APPROACH DURING COMPLETE REMISSION

被引:0
|
作者
CONSOLINI, R
SCAMARDELLA, F
LEGITIMO, A
PUTTI, C
GRANCHI, D
PAOLUCCI, P
LIPPI, A
GUAZZELLI, C
ACQUAVIVA, A
ROSANDA, C
BASSO, G
MACCHIA, P
机构
[1] UNIV PADUA, DIPARTIMENTO PEDIAT, I-35100 PADUA, ITALY
[2] UNIV BOLOGNA, PEDIAT CLIN 3, I-40126 BOLOGNA, ITALY
[3] UNIV FLORENCE, PEDIAT CLIN, I-50121 FLORENCE, ITALY
[4] UNIV SIENA, IST CLIN PEDIAT, I-53100 SIENA, ITALY
[5] IST GIOVANNA GASLINI, GENOA, ITALY
关键词
MINIMAL RESIDUAL DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; COMPLETE REMISSION;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Sensitive methods for detecting residual disease may complement conventional morphology while monitoring the response to treatment in leukemia patients. Methods. We studied minimal residual disease (MRD) by selecting via a colony assay a peripheral blood (PB) cell population enriched in putative malignant cells and detecting occult leukemic cells by double immunologic analysis performed on colonyforming cells (CFC). Using this combined technique we assayed the PB of high risk children with acute lymphoblastic leukemia (ALL) in order to demonstrate possible differences in <<the residual tumor cell burden>> among leukemia patients and to correlate these with a 3-year clinical follow-up. Results. In all 22 patients positive results were obtained for up to 18 months following induction chemotherapy at times of apparent hematologic remission. Common ALL (cALL) patients exhibited a mean of 9.6% cAlla+ cells (range: 2% to 30%), whereas cALL antigen (cALLA) and cALLA/Tdt or CDla/Tdt combination were never found in the colonies derived from healthy individuals. Six out of 22 cALL patients expressed a mean of 16.5% cALLA+/Tdt+ CFC (range: 2% to 35%). Five TALL children presented a mean of 24% CD1a/Tdt+ cells (range: 8% to 44%). Extensive follow-up indicates a correlation between the percentage of CFC Tdt+/lymphoid marker+ cells (more than 10%) and subsequent clinical relapse. In one patient relapse occurred after 16 months with a dramatic increase in the number of leukemic cells. In contrast, the decline in malignant cells, observed in two cases, predicted a favourable course. Five patients tested before autologous bone marrow transplantation (ABMT) presented high number of positive cells and relapsed at various times. Conclusions. We conclude that this approach to the study of MRD could be valuable in monitoring the efficacy of chemotherapy, as well in evaluating the quality of purged marrow.
引用
收藏
页码:297 / 305
页数:9
相关论文
共 50 条
  • [21] Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia
    Rzepiel, Andrea
    Kutszegi, Nora
    Gezsi, Andras
    Sagi, Judit C.
    Egyed, Balint
    Peter, Gyorgy
    Butz, Henriett
    Nyiro, Gabor
    Muller, Judit
    Kovacs, Gabor T.
    Szalai, Csaba
    Semsei, Agnes F.
    Erdelyi, Daniel J.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (01)
  • [22] Characteristics and Therapeutic Targeting of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia
    Jeremias, Irmela
    Schewe, Denis M.
    BIOLOGICAL MECHANISMS OF MINIMAL RESIDUAL DISEASE AND SYSTEMIC CANCER, 2018, 1100 : 127 - 139
  • [23] Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia
    Andrea Rzepiel
    Nóra Kutszegi
    András Gézsi
    Judit C. Sági
    Bálint Egyed
    György Péter
    Henriett Butz
    Gábor Nyírő
    Judit Müller
    Gábor T. Kovács
    Csaba Szalai
    Ágnes F. Semsei
    Dániel J. Erdélyi
    Journal of Translational Medicine, 17
  • [24] Assessment of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: A Multicenter Study From Turkey
    Tufekci, Ozlem
    Evim, Melike Sezgin
    Gunes, Adalet Meral
    Celkan, Tiraje
    Karapinar, Deniz Yilmaz
    Kaya, Zuhre
    Baysal, Birsen
    Baytan, Birol
    Kocak, Ulker
    Yilmaz, Sebnem
    Cinar, Suzan
    Oren, Hale
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2022, 44 (02) : E396 - E402
  • [25] Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse
    Coustan-Smith, E
    Gajjar, A
    Hijiya, N
    Razzouk, BI
    Ribeiro, RC
    Rivera, GK
    Rubnitz, JE
    Sandlund, JT
    Andreansky, M
    Hancock, ML
    Pui, CH
    Campana, D
    LEUKEMIA, 2004, 18 (03) : 499 - 504
  • [26] Biological Markers of High-Risk Childhood Acute Lymphoblastic Leukemia
    He, Jiasen
    Munir, Faryal
    Catueno, Samanta
    Connors, Jeremy S.
    Gibson, Amber
    Robusto, Lindsay
    Mccall, David
    Nunez, Cesar
    Roth, Michael
    Tewari, Priti
    Garces, Sofia
    Cuglievan, Branko
    Garcia, Miriam B.
    CANCERS, 2024, 16 (05)
  • [27] Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia
    Rabin, Karen R.
    Gramatges, M. Monica
    Borowitz, Michael J.
    Palla, Shana L.
    Shi, Xiaodong
    Margolin, Judith F.
    Zweidler-McKay, Patrick A.
    PEDIATRIC BLOOD & CANCER, 2012, 59 (03) : 468 - 474
  • [28] Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse
    E Coustan-Smith
    A Gajjar
    N Hijiya
    B I Razzouk
    R C Ribeiro
    G K Rivera
    J E Rubnitz
    J T Sandlund
    M Andreansky
    M L Hancock
    C-H Pui
    D Campana
    Leukemia, 2004, 18 : 499 - 504
  • [29] Isolated ocular relapse in childhood acute lymphoblastic leukemia during continuing complete remission
    LoCurto, M
    DAngelo, P
    Jankovic, M
    Fugardi, MG
    Ziino, O
    Casale, F
    HAEMATOLOGICA, 1996, 81 (01) : 47 - 50
  • [30] Hematopoietic Stem Cell Transplantation for Adult Philadelphia-Negative Acute Lymphoblastic Leukemia in the First Complete Remission in the Era of Minimal Residual Disease
    Christianne Bourlon
    Dennis Lacayo-Leñero
    Sergio I. Inclán-Alarcón
    Roberta Demichelis-Gómez
    Current Oncology Reports, 2018, 20